Logo image of ZYBT

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis

NASDAQ:ZYBT - Nasdaq - KYG989MS1016 - Common Stock - Currency: USD

5.21  -0.48 (-8.44%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ZYBT. ZYBT was compared to 193 industry peers in the Pharmaceuticals industry. ZYBT has an average financial health and profitability rating. ZYBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ZYBT has reported negative net income.
In the past year ZYBT had a positive cash flow from operations.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 20K 40K 60K

1.2 Ratios

ZYBT's Return On Assets of 12.63% is amongst the best of the industry. ZYBT outperforms 94.82% of its industry peers.
ZYBT has a Return On Equity of 21.87%. This is amongst the best in the industry. ZYBT outperforms 93.78% of its industry peers.
With an excellent Return On Invested Capital value of 21.98%, ZYBT belongs to the best of the industry, outperforming 96.37% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ZYBT is in line with the industry average of 14.92%.
The 3 year average ROIC (14.62%) for ZYBT is below the current ROIC(21.98%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.63%
ROE 21.87%
ROIC 21.98%
ROA(3y)9.55%
ROA(5y)N/A
ROE(3y)16.64%
ROE(5y)N/A
ROIC(3y)14.62%
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 5 10 15

1.3 Margins

ZYBT has a better Profit Margin (18.75%) than 91.71% of its industry peers.
The Operating Margin of ZYBT (27.12%) is better than 92.75% of its industry peers.
ZYBT has a better Gross Margin (61.59%) than 70.98% of its industry peers.
Industry RankSector Rank
OM 27.12%
PM (TTM) 18.75%
GM 61.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ZYBT is creating value.
The number of shares outstanding for ZYBT remains at a similar level compared to 1 year ago.
Compared to 1 year ago, ZYBT has a worse debt to assets ratio.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100K 200K 300K 400K 500K

2.2 Solvency

ZYBT has an Altman-Z score of 5640.04. This indicates that ZYBT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5640.04, ZYBT belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
ZYBT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 3.05
Altman-Z 5640.04
ROIC/WACC2.62
WACC8.39%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100K 200K

2.3 Liquidity

A Current Ratio of 1.38 indicates that ZYBT should not have too much problems paying its short term obligations.
ZYBT's Current ratio of 1.38 is on the low side compared to the rest of the industry. ZYBT is outperformed by 72.54% of its industry peers.
ZYBT has a Quick Ratio of 1.38. This is a bad value and indicates that ZYBT is not financially healthy enough and could expect problems in meeting its short term obligations.
ZYBT's Quick ratio of 0.91 is on the low side compared to the rest of the industry. ZYBT is outperformed by 77.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 0.91
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50K 100K 150K 200K

More info and screens

0

3. Growth

3.1 Past

ZYBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.33%.
ZYBT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.67%.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 50K 100K 150K 200K 250K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZYBT indicates a somewhat cheap valuation: ZYBT is cheaper than 74.09% of the companies listed in the same industry.
ZYBT's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ZYBT is cheaper than 76.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 61761.32
EV/EBITDA 17223.6
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0 0 0 0

4.3 Compensation for Growth

ZYBT has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (8/8/2025, 8:13:31 PM)

5.21

-0.48 (-8.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners6.57%
Ins Owner ChangeN/A
Market Cap246.90M
AnalystsN/A
Price TargetN/A
Short Float %5.91%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP-67.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5394.25
P/FCF 61761.32
P/OCF 32228.13
P/B 6294.56
P/tB 6688.86
EV/EBITDA 17223.6
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY0%
OCF(TTM)0
OCFY0%
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.63%
ROE 21.87%
ROCE 25.44%
ROIC 21.98%
ROICexc 22.53%
ROICexgc 23.68%
OM 27.12%
PM (TTM) 18.75%
GM 61.59%
FCFM 8.73%
ROA(3y)9.55%
ROA(5y)N/A
ROE(3y)16.64%
ROE(5y)N/A
ROIC(3y)14.62%
ROIC(5y)N/A
ROICexc(3y)15.08%
ROICexc(5y)N/A
ROICexgc(3y)15.83%
ROICexgc(5y)N/A
ROCE(3y)16.92%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 3.05
Debt/EBITDA 0
Cap/Depr 112.88%
Cap/Sales 8%
Interest Coverage 20.72
Cash Conversion 48.93%
Profit Quality 46.59%
Current Ratio 1.38
Quick Ratio 0.91
Altman-Z 5640.04
F-Score7
WACC8.39%
ROIC/WACC2.62
Cap/Depr(3y)119.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.43%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y466%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y178.61%
OCF growth 3YN/A
OCF growth 5YN/A